Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

Vaccine. 2005 Jul 1;23(31):4011-5. doi: 10.1016/j.vaccine.2005.03.010. Epub 2005 Apr 7.

Abstract

We have previously shown that HIV p24-like peptides (Vacc-4x) via activation of skin dendritic cells induced immune responses in 90% of HIV patients on highly active antiretroviral treatment (HAART). These patients (n=38) were here subjected to a final 14-week interruption of HAART. Patients with the highest delayed type hypersensitivity (DTH) responses to Vacc-4x-peptides before treatment interruption tended to achieve lower actual HIV RNA levels at the end of the study compared to Vacc-4x DTH low-responders (p=0.08) and significantly so in terms of viral loads relative to their individual pre-HAART HIV RNA set-points (p=0.04). CD4+ lymphocyte counts were maintained only among DTH high responders but decreased in the other patients during recurrent viremia (p</=0.02). No other pre-study differences in HIV history or p24-responses were found.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / immunology*
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • HIV Core Protein p24 / immunology
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans
  • Hypersensitivity, Delayed
  • RNA, Viral / blood
  • Viral Load

Substances

  • AIDS Vaccines
  • HIV Core Protein p24
  • RNA, Viral
  • Vacc-4x